NCT01502358View on ClinicalTrials.gov

Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Dengue DiseaseDengue Fever
Interventions
BIOLOGICAL

Tetravalent Dengue Vaccine (TVDV)

Low dose delivered intramuscularly on Study Days 0, 30 and 90

BIOLOGICAL

Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)

Low dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90

BIOLOGICAL

Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose)

High dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90

Trial Locations (1)

20702

Walter Reed Army Institute of Research and Clinical Trial Center (WRAIR CTC), Silver Spring

Sponsors
All Listed Sponsors
collaborator

Vical

INDUSTRY

collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

collaborator

Naval Medical Research Center

FED

lead

U.S. Army Medical Research and Development Command

FED

NCT01502358 - Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease | Biotech Hunter | Biotech Hunter